Abstract
Multiple myeloma (MM) treatment remains challenging due to its relapsed/refractory disease course as well as intra- and inter-patient heterogeneity. Cellular immunotherapies, especially chimeric antigen receptor (CAR)-T cells targeting B cell maturation antigen (BCMA), mark a major breakthrough, achieving long-lasting remissions and instilling hope for a potential cure. While ongoing clinical trials are increasingly driving approved cellular products towards earlier lines of therapy, novel targets as well as advanced approaches employing natural killer (NK) cells or dendritic cell (DC) vaccines are currently under investigation. Treatment resistance, driven by tumor-intrinsic factors such as antigen escape and the intricate dynamics of the tumor microenvironment (TME), along with emerging side effects such as movement and neurocognitive treatment-emergent adverse events (MNTs), are the major limitations of approved cellular therapies. To improve efficacy and overcome resistance, cutting-edge research is exploring strategies to target the microenvironment as well as synergistic combinatorial approaches. Recent advances in CAR-T cell production involve shortened manufacturing protocols and “off-the-shelf” CAR-T cells, aiming at decreasing socioeconomic barriers and thereby increasing patient access to this potential lifesaving therapy. In this review, we provide an extensive overview of the evolving field of cellular therapies for MM, underlining the potential to achieve long-lasting responses.
Funding Information
  • Interdisciplinary Center for Clinical Research (IZKF) (Z-2_CSP_2022-27, 13N15986, TRR338, 03ZU1111BA, 101016909, 754658, 853988, 945393)
  • Mildred Scheel Early Career Cancer Center (Z-2_CSP_2022-27, 13N15986, TRR338, 03ZU1111BA, 101016909, 754658, 853988, 945393)
  • Paula and Rodger Riney Foundation Translational Research Award (Z-2_CSP_2022-27, 13N15986, TRR338, 03ZU1111BA, 101016909, 754658, 853988, 945393)
  • German José Carreras Leukemia Foundation (Z-2_CSP_2022-27, 13N15986, TRR338, 03ZU1111BA, 101016909, 754658, 853988, 945393)
  • DKMS John Hansen Research Grant (Z-2_CSP_2022-27, 13N15986, TRR338, 03ZU1111BA, 101016909, 754658, 853988, 945393)
  • German Ministry for Science and Education (BMBF, Bundesministerium für Bildung und Forschung) (Z-2_CSP_2022-27, 13N15986, TRR338, 03ZU1111BA, 101016909, 754658, 853988, 945393)
  • German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) (Z-2_CSP_2022-27, 13N15986, TRR338, 03ZU1111BA, 101016909, 754658, 853988, 945393)
  • Stiftung Forschung hilft (Z-2_CSP_2022-27, 13N15986, TRR338, 03ZU1111BA, 101016909, 754658, 853988, 945393)
  • BMBF SaxoCell Cluster for Future (Z-2_CSP_2022-27, 13N15986, TRR338, 03ZU1111BA, 101016909, 754658, 853988, 945393)
  • European Union (Z-2_CSP_2022-27, 13N15986, TRR338, 03ZU1111BA, 101016909, 754658, 853988, 945393)

This publication has 157 references indexed in Scilit: